Why Enzymotec (ENZY) Plunged to a One-Year Low Today

NEW YORK (TheStreet) -- Enzymotec  (ENZY) plunged more than 30% to a one-year low of $13.60 on Wednesday after the company reported mixed first-quarter results.

The company reported earnings of 24 cents a share, which beat the consensus estimate of 17 cents from analysts polled by Thomson Reuters. Revenue totaled $17.9 million, which was short of analysts' estimate of $19.4 million.

Enzymotec also issued guidance for the full year 2014 of 64 cents a share to 94 cents a share, while analysts expect 86 cents a share. The company expects full year revenue based on the proportionate consolidation method of $90 million to $110 million, while analysts expect $92.95 million. Based on the equity method, Enzymotec expects revenue of $68 million to $85 million.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

The stock was down 28.13% to $14.54 at 12:32 p.m.

ENZY Chart

ENZY data by YCharts

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

If you liked this article you might like

Which Stocks Hurt Billionaire Portfolios the Most in 2014?

Which Stocks Hurt Billionaire Portfolios the Most in 2014?

Enzymotec: John Paulson Bought 20 Percent - Should You Follow Suit?

Enzymotec: John Paulson Bought 20 Percent - Should You Follow Suit?

Medical IPOs: Foundation, Enzymotec and Premier

Medical IPOs: Foundation, Enzymotec and Premier

Ivy League Regatta Rows Into Headwind

Ivy League Regatta Rows Into Headwind